{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for lactic root_codes_url in Code URL (approximate match)
Status:
US Approved Rx
(1981)
Source:
NDA018469
(1981)
Source URL:
First marketed in 1921
Source:
Emulsion of Cod Liver Oil with Calcium Phosphate N.F.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).
Status:
US Approved Rx
(1984)
Source:
ANDA088638
(1984)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.
Status:
US Approved OTC
Source:
21 CFR 331.11(e) antacid:citrate-containing citrate (containing active ingredients: citrate ion, as citric acid or salt)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.
Status:
Investigational
Source:
NCT00942656: Not Applicable Interventional Completed Cardiovascular Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Vaccenic acid (VA) (t11 octadecenoic acid) is a positional and geometric isomer of oleic acid (c9-octadecenoic acid), and is the predominant trans monoene in ruminant fats (50%–80% of total trans content). Dietary VA can be desaturated to cis-9,trans-11 conjugated
linoleic acid (c9,t11-CLA) in ruminants, rodents,
and humans. Hydrogenated plant oils are another source of VA in
the diet, and it has been recently estimated that this source
may contribute to about 13%–17% of total VA intake. In contrast to suggestions from the epidemiological studies,
the majority of studies using cancer cell lines (Awad et
al. 1995; Miller et al. 2003) or rodent tumors (Banni et al.
2001; Corl et al. 2003; Ip et al. 1999; Sauer et al. 2004)
have demonstrated that VA reduces cell growth and (or) tumor
metabolism. Animal and in vitro studies suggest that
the anti-cancer properties of VA are due, in part, to the in
vivo conversion of VA to c9,t11-CLA. However, several additional
mechanisms for the anti-cancer effects of VA have
been proposed, including changes in phosphatidylinositol
hydrolysis, reduced proliferation, increased apoptosis, and inhibition
of fatty acid uptake. In conclusion,
although the epidemiological evidence of VA intake
and cancer risk suggests a positive relationship, this is not
supported by the few animal studies that have been performed. The majority of the studies suggest that any health benefit
of VA may be conferred by in vivo mammalian conversion
of VA to c9,t11-CLA. VA acts as a partial agonist to both peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ in vitro, with similar affinity compared to commonly known PPAR agonists. Hypolipidemic and
antihypertrophic bioactivity of VA is potentially mediated
via PPAR-/-dependent pathways.
Status:
Possibly Marketed Outside US
Source:
NCT03892447: Phase 4 Interventional Unknown status Children AKI Patients
(2019)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Possibly Marketed Outside US
Source:
24 HOUR PIMPLE PUNISHER
Source URL:
First approved in 2003
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Oleanolic acid or oleanic acid is a naturally occurring pentacyclic triterpenoid. It is widely distributed in food and plants where it exists as a free acid or as an aglycone of triterpenoid saponins. Oleanolic acid protects the liver from acute chemically induced liver injury, fibrosis and cirrhosis caused by chronic liver diseases. Its possess cytotoxic activity against tumor cell lines
Status:
Possibly Marketed Outside US
Source:
NCT03642535: Phase 4 Interventional Recruiting Actinic Keratoses
(2018)
Source URL:
First approved in 1994
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Alpha-linolenic acid (ALA), an 18-carbon omega-3 essential fatty acid, is the precursor of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA cannot be synthesized by humans and therefore must be entirely acquired from exogenous sources. Evidence for the essentiality of ALA was first provided by a study showing that ALA supplementation reversed the abnormal neurologic signs observed in a 6-year-old girl who suffered from sensory loss and visual complications. Most of the ALA is catabolized via beta-oxidation for energy generation, and a small proportion of it undergoes conversion to produce another two potent members of omega-3 PUFA family: EPA and DHA. Delta 6 desaturase (D6D) enzyme is responsible the conversion of ALA to DHA. Although not conclusive, it was suggested, that the benefits associated with ALA seem to stem mainly from EPA and DHA, and as major consequence of ALA deficiency it appears that EPA and DHA are not adequately produced.
Status:
Possibly Marketed Outside US
Source:
NCT00442962: Phase 4 Interventional Completed HIV Infections
(2007)
Source URL:
First approved in 1946
Source:
NDA006035
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Maleic acid monosodium salt. Used in water soluble polymers preparation.